First Implant of the Minder® System in the US

- The Perelman School of Medicine at the University of Pennsylvania implants the first patient in the United States with the Minder System as part of Epiminder's DETECT Study.

- Four other sites, the Mayo Clinic Rochester, Mayo Clinic Jacksonville, and Mayo Clinic Phoenix, and Beth Israel Deaconess Medical Center, have signed on to and are actively recruiting patients for the DETECT study, the first Randomized Controlled Trial for continuous electroencephalography (EEG) monitoring in drug resistant epilepsy.

Melbourne, Australia & Dallas, United States – January 16, 2026 – Epiminder Limited (ASX: EPI), a pioneer medical device company developing breakthrough epilepsy monitoring technology, today announced the first implant of the Minder System in the United States. The Perelman School of Medicine at the University of Pennsylvania, the first site to join the Diagnosing Epilepsy To Effect Change (DETECT) study (NCT07110337), has enrolled and implanted the first study patient. Additionally, Epiminder announced that four other sites have enrolled for the study and are actively recruiting patients, including the Mayo Clinic Rochester, Mayo Clinic Jacksonville and Mayo Clinic Phoenix, and Beth Israel Deaconess Medical Center.

The DETECT study is the first Randomized Controlled Trial to compare patients who are implanted with Minder to standard of care monitoring to identify clinically actionable events in patients with drug-resistant epilepsy. In the six-month study, 210 patients will receive the implant at up to 25 sites in the United States. The goal of the study is to demonstrate that continuous EEG monitoring is superior to using standard of care in identifying clinically actionable events in patients with drug-resistant epilepsy.

The Perelman School of Medicine at the University of Pennsylvania's Assistant Professor of Clinical Neurology, Dr. Taneeta Mindy Ganguly, who specializes in epilepsy said, "I am thrilled to be able to offer this innovative technology as we implant our first patient in the DETECT study. Standard EEG methods do not offer the long-term EEG monitoring necessary to make informed management decisions for many of our patients. The ability to provide continuous, high-fidelity monitoring over months and years bridges that critical diagnostic gap with far reaching implications for patients and providers. The long-term EEG data obtained is key in unlocking the future of epilepsy care, allowing us to achieving better outcomes and quality of life for our patients."

Rohan Hoare, CEO of Epiminder, said, "This first US implant of our Minder device marks a watershed moment for Epiminder and the global epilepsy community. We are excited to take the next step in translating years of rigorous scientific development and clinical validation into real-world impact for patients who have exhausted traditional monitoring options. Dr. Ganguly and her team at Penn Medicine represent the exceptional clinicians who will help us begin to unlock Minder's full potential. Their expertise

and dedication to advancing drug-resistant epilepsy care embody exactly why we built this device. Consistent with our commercialization strategy, with each patient enrolled in DETECT, we move closer to our mission: empowering clinicians with objective, continuous brain activity data and ultimately providing the 52 million people living with epilepsy worldwide with the answers, insights, and hope they deserve. This study is just the beginning of what we believe will be a fundamental transformation in how the world diagnoses and manages epilepsy."

To learn more about the DETECT study, please visit www.clinicaltrials.gov and search for NCT07110337.

Authorisation

This announcement has been authorised for lodgement to the ASX by Epiminder's Board of Directors.

Investor & Media Enquiries

Media contacts: Mark Gardy 0412 376817 or Stephen Dabkowski 0419 880486

For any Company queries please contact Epiminder at investors@epiminder.com

+++

Follow Epiminder on LinkedIn and explore Epiminder.com for more information.

About Minder

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder's long-term monitoring of patients outside of a controlled clinical environment provides clinicians with the data needed to remotely monitor and assess the patient's condition, including determining the effectiveness of drug therapies and other interventions.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

epiminder

About Mayo Clinic

Mayo Clinic is the largest integrated, not-for-profit medical group practice in the world. We're building the future, one where the best possible care is available to everyone — and more people can heal at home. Our relentless research turns into earlier diagnoses and new cures. That's how we inspire hope in those who need it most.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox.

Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.